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ABSTRACT

EXPOSURE TO POLYBROMINATED DIPHENYL ETHERS (PBDEs)
SUPPRESSES THE RELEASE OF PRO-INFLAMMATORY PRODUCTS BY
ALVEOLAR MACROPHAGES IN VITRO
by
Stephen R. Hennigar
University of New Hampshire, May, 2010

Endocrine disrupting chemicals have adverse effects on immune function that
may result in respiratory conditions. Inhalation of dust is a major route of exposure to
PBDEs; however, the impact of PBDEs on the immune response is unclear. The objective
of this in vitro study was to determine the impact of PBDEs on the release of proinflammatory cytokines by activated alveolar macrophages. Porcine alveolar
macrophages were grown in RPMI growth media supplemented with 10% porcine serum
and incubated for 24-hours. After 24-hours, cells were activated by inoculation with
PMA. In addition to PMA, different concentrations of the PBDE mixture DE-71 were
introduced to the wells. After 6-hour incubation, conditioned media was removed and
analyzed. Cells exposed to PMA and PBDEs released significantly less pro-inflammatory
cytokines compared to controls. Suppression of pro-inflammatory cytokinescharacteristic of a compromised immune system- suggests that persistent exposure to
PBDEs may increase the susceptibility to respiratory conditions.

x

CHAPTER I

LITERATURE REVIEW

Preface
The purpose of this literature review is to examine the growing evidence that
certain classes of synthetic chemicals are biologically active and may have subtle yet
profound effects on the health of humans and wildlife. The literature review will begin
with a brief discussion of environmental pollutants, specifically chemicals that have been
shown to disrupt the endocrine system (i.e. endocrine disruptors). In doing so, I will focus
on chemicals found to mimic the hormone estrogen (i.e. xenoestrogens). A brief history
of some common xenoestrogens, their origins, and some of the plausible mechanisms of
action related to health will be addressed. The review will then focus on one class of
environmental pollutants and suspected xenoestrogen, polybrominated diphenyl ethers
(PBDEs) - their properties, prevalence, routes of exposure, and health consequences.
Lastly, a brief review of innate immunity as it relates to airway health will be presented.
The possible interaction between PBDEs and innate immunity, specifically as it relates to
alveolar macrophage function, will be the focus of the study reported in Chapter II.
Environmental Pollutants
Manufacturers have saturated the environment with synthetic chemicals since the
Industrial Revolution. Some of the earliest and most well known chemicals manufactured
included bisphenol A (BPA), originally used as a synthetic estrogen in the early 1920s

1

and now used in plastics; polychlorinated biphenyls (PCBs), introduced in 1929 and used
in electrical equipment as well as many other products; and
dichlorodiphenyltrichloroethane (DDT), introduced as a pesticide in 1938. Post World
War II, synthetic chemical production increased exponentially, when companies
previously manufacturing chemicals used for warfare, began the wide-scale manufacture
of common domestic products (1). Currently, synthetic chemical production is at an all
time high. Tens of thousands of chemicals are used in the manufacture of common
products such as dyes, flame retardants, flavorings, medicines, perfumes, pesticides,
pigments, plastics, plasticizers, resins, solvents, and countless others products (2). The
U.S. Environmental Protection Agency (EPA) estimates that 87,000 chemicals are in use
today, amounting to billions of pounds of chemicals produced annually (1). Although
many of these chemicals were developed with good intentions and some are important for
safety, they have recently been implicated with many unintended health risks.
In 1991, a group of scientists convened in Racine, Wisconsin to discuss the
growing body of evidence that suggests many of these man-made chemicals have the
potential to disrupt the endocrine system. The outcome of the conference, and what is
now considered a monumental document, was the Wingspread Consensus Statement.
Chaired by Dr. Theo Colborn, the group appropriately coined these synthetic chemicals
"endocrine disruptors" (3). An endocrine disruptor is defined by the U.S. EPA as "an
exogenous agent that interferes with synthesis, secretion, transport, metabolism, binding
action, or elimination of natural blood-borne hormones that are present in the body and
are responsible for homeostasis, reproduction, and developmental process." DiamantiKandarakis et al. (2009), extend this definition to say "from a physiological perspective,
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an endocrine-disrupting substance is a compound, either natural or synthetic, which,
through environmental or inappropriate developmental exposures, alters the hormonal
and homeostatic systems that enable the organism to communicate with and respond to
its environment" (4).
The endocrine system consists of glands (Figure 1), hormone-secreting cells, and
target cells, all of which regulate important biological processes such as metabolism,
growth, reproduction, and many other functions through the production and release of
chemical messengers, called hormones. A hormone is a protein, steroid, amine, or
eicosanoid, secreted by a cell that travels to a target cell to elicit a specific biological
response via a receptor.
The glands of the endocrine system and the hormones they release influence the
function of many biological processes. Other systems (i.e. nervous and immune systems)
use different chemical messengers such as neurosecretions and cytokines respectively, to
communicate. Hormones and chemical messengers allow for cross-talk to occur between
these integrating systems (Figure 2). A wide range of hormonally-regulated processes
such as those shown in Figure 3 are therefore vulnerable to the subtle disruption of
hormone mimicking chemicals (4).
Endocrine disruptors mimic or interfere with endogenous signaling pathways and
can therefore disrupt receptor signaling. For example, certain chemicals act like the
hormone estrogen (i.e xenoestrogens). Xenoestrogens are capable of interfering with
estrogen signaling in many different ways. Endocrine disruptors (including
xenoestrogens) have the ability to bind directly to specific hormone receptors (i.e.
estrogen, androgen, and thyroid hormone receptors) and affect hormone signaling; or
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they can bind to orphan receptors, such as the aryl hydrocarbon receptor (AhR) or the
steroid and xenobiotic receptor (SXR) and indirectly affect hormone signaling (5). Once
bound, endocrine disruptors can act as agonists and mimic the action of a naturally
occurring hormone (e.g. estrogens, androgens, and thyroid hormone) and its function; or
act as antagonists and block the endogenous hormone from binding (e.g. anti-estrogens
such as tamoxifen). To further complicate matters, most endocrine disruptors interfere
with multiple hormone signaling pathways. For example, DDT has been shown to
interact with estrogen and androgen receptors (5). Because of these capabilities, as well
as the complex interactions of the endocrine system with many other systems of the body,
endocrine disruptors have the ability to subversively affect health in a number of ways.
DDT was first made in 1873; however, it was not until 1938 that a Swiss chemist
recognized its effectiveness as an insecticide. Incidentally, Dr. Paul Muller went on to
win the Nobel Prize for the discovery in 1948. Due to its effectiveness, the production
and use of DDT increased greatly in the 1940s. Shortly thereafter, it was discovered that
DDT impacted the sexual development of birds; and later reports in humans indicated an
increased risk of cancers, reproductive effects, and neurological toxicity (6). As a result,
DDT was banned in the U.S. in 1972. It still, however, continues to be used in other parts
of the world and continues to persist in the environment decades after the U.S. ban.
The wide-scale production of PCBs is another example of an endocrine disrupting
chemical shown to have adverse affects on health. PCBs are flame retardant, chemically
stable, have a high boiling point, and have electrical insulating properties. They are
therefore found in a number of products including: electrical, heat transfer, and hydraulic
equipment, plasticizers in paints, plastics, and rubber products, pigments, dyes, and
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carbonless copy paper, as well as many other products (7). PCBs disrupt endocrine
signaling by interacting with the AhR (8) as well as the thyroid hormone receptor (4).
Studies have indicated that PCBs adversely affect the reproductive system (e.g. reduced
birth rate, conception rates, and live birth rates in monkeys and other animals, and
reduced sperm counts in rats), the nervous system (e.g. deficits in neurological
development), the endocrine system (e.g. thyroid hormone disruption), and the immune
system (e.g. reduced immune response, decreased resistance to infection, and an
increased susceptibility to pneumonia and viral infections) (6, 7). They have also been
shown to cause cancer in both animals and humans, although some suggest that cancer is
a result of the PCB-induced suppression of the immune system (6). Due to their toxic
effects on health, PCBs were banned from manufacture in the U.S. in 1979. Like most
endocrine disruptors, however, PCBs were developed to have an exceptionally long halflife. So similar to DDT, PCBs persist in the environment decades after being banned.
Since the Wingspread Conference numerous other chemicals found in many of
the products that we, as humans encounter throughout our everyday lives have emerged
as endocrine disruptors. Table 1 includes main groups of endocrine disrupting chemicals
and some examples of each. Examples include but are not limited to synthetic industrial
chemicals [dioxins, polybrominated diphenyl ethers (PBDEs), PCBs], plastics [bisphenol
A (BPA)], plasticizers (phthalates), insecticides (carbaryl, DDT, dieldrin), fungicides
(hexachlorobenzene), and pharmaceutical agents [diethylstilbestrol (DES)].

Polybrominated Diphenyl Ethers (PBDEs)
Polybrominated diphenyl ethers (PBDEs) are a class of synthetic chemicals that
are used extensively as flame retardants in numerous household and commercial products
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including plastics in electrical appliances, televisions, and computers; and foams, carpets,
and upholstery found in furniture, automobiles, and airplanes (9). PBDEs are added to
these products to reduce their flammability and decrease the burning rate, so that in the
event of a fire there is increased time to escape. Although designed to save lives,
evidence is mounting that PBDEs may be doing more harm than good.
Unlike the long banned PCBs and dichlorodiphenyltrichloroethane (DDT), there
is continued widespread production and use of PBDEs. Consequently, while the levels of
PCBs and DDT have decreased since being banned, the levels of PBDEs found in human
blood, milk, and tissue have increased exponentially (10) - with levels doubling every 35 years (11). Because PBDEs have a similar structure and many of the same properties of
DDT and PCBs (Figure 4), there is reason to believe that exposure to PBDEs may result
in similar health complications associated with these previously banned chemicals.
PBDEs consist of two phenyl rings joined by an ether linkage; differing in the
number and position of the bromine atoms attached to the rings (Figure 4A). There are
209 possible configurations of PBDEs, and these congeners are grouped according to the
number of bromine atoms in the molecule (i.e. 4-10). PBDEs are commercially
developed as one of three formulations, named for the number of bromine atoms they
contain: the penta- formulation, commercially known as DE-71 and Bromkal 70-5DE; the
octa- formulation, commercially known as DE-79; and decaBDEs, commercially known
as DE-83R (12). PentaBDEs are primarily composed of penta- congeners (50-62% by
weight); octaBDEs are made up of hepta- (45%) and octa- (33%) congeners; and
decaBDEs consists of BDE-209 (97-99%) (12). Table 2 lists some of the major PBDE
congeners and mixtures. It is important to note that five of the 209 different congeners
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account for 90% of the PBDEs found in human tissues (BDE-47, -99, -100, -153, -154)
(13) and that collectively these congeners make up the PBDE mixture, DE-71.
Furthermore, it is suspected that the pentaBDEs are the major contributor to the burden of
PBDEs in both the environment and humans (12).
The penta- and octaBDEs are more readily absorbed, more bioaccumulative, more
bioactive, and are eliminated more slowly compared to the decaBDEs. The penta- and
octaBDEs were first reported to be biologically active as neurotoxins and endocrine
disruptors in laboratory animals (14). As a result, production of these congeners is
banned in the European Union (EU) and several states in the U.S. The decaBDEs
however, are still produced and used globally [according to Inventory Update Reports
(IUR) between 50-100 million pounds were manufactured or imported in the U.S. in
2005 - the same as was reported in 2002 (15)]. Because PBDEs are not fixed in the
polymer product by chemical bonding, bromine atoms are lost spontaneously over the
lifetime of the product. Thus, over time, the more highly brominated decaBDEs can break
down by photolytic or biological mechanisms and form the lower brominated, more
bioactive and bioaccumulative PBDE congeners (12, 15, 16).
PBDEs are added to a wide variety of consumer products. PentaBDEs are most
often found in polyurethane foam such as that used in couches, chairs, and automobile
seats. OctaBDEs are used in televisions, computers, and other small appliances such as
telephones and electronics; and decaBDEs are also used in plastics for consumer
electronics, as well as plastic furniture and toys, wire insulation, and textiles such as
upholstery. For reasons cited earlier, these products leak bromine atoms into ambient air
with continued use and wear and tear over time.
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Due to the ubiquity and persistence of PBDEs in nature, they are ingested
regularly and accumulate readily in lipids of body tissues. They have been detected in
indoor and outdoor air, dust, soil, streams and lakes and tissues of coldwater fish and
domestic animals. They have also been found in the adipose, serum, and breast milk of
humans (17). One source of exposure to PBDEs is food. Typically, animal-based foods
contain higher concentrations of PBDEs than plant-based foods (18). Fish, meat, and
dairy products contain the highest concentrations of PBDEs (19, 20). Due to its
popularity in the Westernized diet, meat is suspected to be the major dietary source of
PBDEs in the U.S. (20). Interestingly, a recent study showed that vegetarians have lower
concentrations of PBDEs compared to omnivores and that serum PBDE concentrations
increased in individuals who reported consuming a low, medium, and high amount of
poultry and red-meat (21).
The levels of PBDEs found in human tissues in North Americans are of major
concern, with levels one to two orders of magnitude higher than those detected in Europe
and Japan (16). Lorber (2008), reports that similar levels of PBDEs are found in food
while higher levels are found in soil, house dust, and air in the U.S. compared to abroad
(12). In fact, recent evidence shows that inadvertent exposure to dust contributes more to
the total body burden of PBDEs than diet (22). Furthermore, in a recent study it was
estimated that 82% of total PBDE intake was obtained by inhalation of house dust (12,
23).
PBDEs are lipophilic and accumulate readily in adipose tissue and breast milk of
nursing mothers (22). Table 3 shows representative serum levels of PBDEs from a family
from Northern California in 2004. Due to chronic PBDE exposure to the fetus via the
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maternal circulation during pregnancy, to nursing infants via breast milk, and to children
via house dust, infants and children have a particularly high body burden of PBDEs,
reported as 3-4 times higher than adults (16). Moreover, exposure of fetuses, infants, and
children to PBDEs during critical times of development raises increasing health concerns.
A growing body of literature suggests that PBDEs may be implicated in a number
of potential health complications. Studies have linked PBDE exposure to altered function
of thyroid, liver, and nervous systems, as well as impairment of behavioral development,
disruption of reproductive hormones, and alterations in immune function. For example,
PBDEs reported to lower thyroid hormone in animals and act as either agonists or
antagonists at the androgen, progesterone, and estrogen receptors (17).
Studies documenting the effects of PBDEs on immune function are limited. In
2005, Reistad and Mariussen found that in vitro exposure of human neutrophil
granulocytes to the DE-71 mixture induced respiratory burst (24). Fernie et al. (2005)
exposed nestling American kestrels to pentaBDE congeners (-47, -99, -100, -153) and
assessed the T-cell mediated-immune response via phytohemagglutinin (PHA) skin
response test and humoral-immunity by measuring total plasma antibody (IgM + IgG)
titers. PBDE-exposed birds showed an initial stimulation in the T-cell response that was
suppressed as the concentrations of BDE-47 increased. Humoral immunity was also
compromised, as kestrels exposed to PBDEs showed suppressed antibody titers.
Researchers also saw fewer germinal centers in the spleen, reduced apoptosis in the
bursa, and increased macrophages in the thymus. Collectively, these data suggested that
exposure to PBDEs could result in an inadequate immune response to viruses and other
potentially harmful pathogens (25). More recently, Lundgren et al. (2009) examined the
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effects of PBDEs on cytokine responses in virus-infected mice. They found a suppression
of cytokine [interleukin-13 (IL-13) and interferon-y (IFN-y)] and chemokine
[macrophage inflammatory protein-1|3 (MIP-1|3), regulated upon activation, normal Tcell expressed and presumably secreted (RANTES), and keratinocyte chemoattractant
(KC)] levels in the serum of non-infected mice exposed to PBDEs, indicating that PBDEs
may block immune signaling (26).
Because PBDEs have been implicated as xenoestrogens, their influence on
immune function may be explained, in part, by the effects estrogen has on the immune
system. Whether PBDEs are having similar effects on immune function and whether
PBDEs are binding to the estrogen receptor to exert these effects remains to be
determined. Due to limited studies examining the effects of PBDEs on the immune
system and the conflicting results of the few studies conducted to date - more research in
this area is warranted.

Immune Function
The immune system is an intricate network of specialized cells dedicated to
defending the body against foreign pathogens (Figure 5). A normally functioning
immune system is crucial to survival. Infection occurs when the host encounters a
pathogen that invades and infects the host's respiratory mucosal tissues.
Figure 6 is an overview of the immune defense mechanisms against respiratory
pathogens. Once the pathogen invades the cells, the innate immune response is initiated.
Antigen presenting cells such as macrophages and dendritic cells are activated and
produce an array of cytokines. For example, interferon-a/|3 (IFN-a/p) is secreted and
prevents viral replication. Also, classically-activated macrophages secrete the pro-
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inflammatory cytokines tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and
interleukin-ip (IL-1|3), that induce the acute phase inflammatory (innate) response. The
latter includes an increase in complement proteins, extravasation of leukocytes, and
antigen presentation. Dendritic cells secrete interleukin-12 (IL-12), leading to the
differentiation of nai've TNEIPER (Th) cells into T h I cells.
Th cells regulate the development of acquired immunity toward either a ThI or
Th2 pathway. ThI cells secrete interleukin-2 (IL-2) and IFN-y. IL-2 encourages the
activation of cytotoxic T-cells, which travel to the infected area. Cytotoxic T-cells
recognize antigen presented by major histocompatibility complex (MHC) class I
molecules, which upon binding lead to cell death by apoptosis. Similarly, IFN-y activates
natural killer (NK) cells to increase cell death by apoptosis. Macrophages then
phagocytose and clean up the apoptotic cells and the intracellular antigen can then be
cross-presented to cytotoxic T-cells.
Naive Th cells also differentiate into Th2 cells that secrete the anti-inflammatory
cytokines interleukin-10 (IL-10) and interleukin-4 (IL-4). IL-10 suppresses the proinflammatory cytokines, while IL-4 induces the differentiation of B cells into plasma and
memory B cells. Plasma cells secrete specific antibodies that bind infected cells and lead
to apoptosis.
Recent evidence suggests that macrophages in the lung may be important
modulators of immunity, directing Th cells toward either a ThI or Th2 response (27).
Macrophages are sentinel cells that respond to foreign antigens by secreting
inflammatory cytokines and eicosanoids. Cytokines and eicosanoids are produced by the
macrophage in response to external stimuli and influence other cells by binding to a
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specific receptor on their surface. The major pro-inflammatory cytokines produced by
macrophages include TNF-a, IL-6, IL-1|3, and the eicosanoid prostaglandin E2 ( P G E 2 ) . In
addition, macrophages secrete the anti-inflammatory cytokine, IL-10.
Pro-inflammatory cytokines are produced through the activation of the
transcription factor, nuclear factor-KB ( N F - K B ) . In the activated form, N F - K B is a
heterodimer consisting of two proteins, a p65 subunit and a p50 subunit. In unstimulated
cells, N F - K B is located in the cytoplasm bound to an inhibitory protein, IK-B that
prevents it from entering the nucleus. Upon activation, IK-B kinase (IKK) phosphorylates
IK-B,

resulting in degradation of the inhibitory protein and allowing N F - K B to translocate

to the nucleus to initiate the transcription of various cytokine genes. Many stimuli have
been shown to activate N F - K B including cytokines such as T N F - a and protein kinase C
activators such as PMA, a phorbol ester, and lipopolysaccharide (LPS), a bacterial
endotoxin (28).
In healthy tissue, the macrophage is in a resting state. Once a pathogen is
encountered, the macrophage initiates the inflammation process, activating and secreting
pro-inflammatory cytokines. The release of cytokines results in vasodilation and
increased vascular permeability that allows fluid, protein, and inflammatory cells to leave
the blood stream and enter the tissue. As a result, the infected tissue becomes inflamed,
causing the characteristic redness, heat, swelling, and pain associated with infection - a
response that is necessary in order to resolve the infection.
Through the production of a multitude of different chemical signals and through
the expression of a number of different receptors, macrophages have the potential to
communicate via a number of different pathways. For example, macrophages express the
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estrogen receptor and have been shown to be regulated by estrogen (29). Furthermore,
estrogen has an inhibitory effect on TNF-a and other cytokines in may different cell
types, such as human promonocytic cells, rat microglia, and mouse dendritic cells
(reviewed by (29). In this review Straub (2007), claims that these results are most likely
due to inhibition of N F - K B (29). Ghisletti et al. (2005), provide evidence that the
inhibitory effects of estrogen on N F - K B are mediated by blocking the binding and
transcriptional activity of p65 and preventing nuclear translocation (29, 30). These latter
findings suggest activation of macrophages and initiation of the initiation of
inflammatory signals are modulated by estrogen. Whether similar effects on macrophage
function occur in response to PBDEs, a suspected xenoestrogen, remains to be
determined.
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CHAPTER II

EXPOSURE TO POLYBROMINATED DIPHENYL ETHERS (PBDEs)
SUPPRESSES THE RELEASE OF PRO-INFLAMMATORY PRODUCTS BY
ALVEOLAR MACROPHAGES IN VITRO

Abstract
Endocrine disrupting chemicals have adverse effects on immune function that
may result in respiratory conditions. Inhalation of dust is a major route of exposure to one
endocrine disrupting chemical and xenoestrogen, polybrominated diphenyl ethers
(PBDEs). The impact of PBDEs on the immune response, however, is unclear. The
objective of this in vitro study was to determine the impact of PBDEs on the release of
pro-inflammatory cytokines and eicosanoids by activated alveolar macrophages and to
determine whether the effects are estrogen-receptor dependent. Porcine alveolar
macrophages were grown in RPMI growth media supplemented with 10% porcine serum
and incubated for 24-hours (5% CO2, 37°C). After 24-hours, cells were activated by
inoculation with phorbol 12-myristate 13-acetate (PMA) (0.01 mg/ml) and ionomycin
(0.05 mg/ml) in 1% DMSO. In addition to PMA, different concentrations of the
pentaBDE mixture, DE-71, were introduced to the wells. To determine if the effects of
PBDEs were similar to the effects of estrogen on cytokine release and whether PBDEs
were working through the estrogen receptor, different concentrations of 17|3-estradiol and
the anti-estrogen, tamoxifen, were added to the wells. After 6-hour incubation in each of
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the experiments, conditioned media was removed and stored at -80°C until analysis of the
following cytokines and PGE2 via ELISA: TNF-a, IL-6, IL-1(3, and IL-10. Cells exposed
to PMA and PBDEs released significantly less pro-inflammatory cytokines (TNF-a and
IL-6) and PGE2 compared to controls; IL-1(3 and IL-10 were not detected in the culture
medium. Cells exposed to PMA and estrogen released significantly less TNF-a compared
to controls and the addition of tamoxifen did not restore the inhibitory effect of PBDEs
on TNF-a release. Thus, the suppression of TNF-a with DE-71 is similar to that of
estrogen; however, the inhibitory effects of DE-71 are not mediated via the estrogen
receptor. Suppression of pro-inflammatory cytokines- characteristic of a compromised
immune system- suggests that persistent exposure to PBDEs may increase the
susceptibility to respiratory disorders.

Introduction
Respiratory infections (e.g. rhinovirus and influenza) are the most prevalent and
pathogenic form of infectious disease (31, 32). Infection occurs when the host encounters
a pathogen, which invades and infects the host's respiratory mucosal tissues. Once the
pathogen invades the cells, the innate immune response is initiated (see Chapter I:
Immune Response for a detailed explanation). The immune response is orchestrated by a
number of finely tuned immune cells. When all is functioning normally, the process of
resolving an infection takes approximately 7-14 days and is characterized by coughing,
sore throat, fever, nasal/ear congestion, fatigue, and body aches (31). When the immune
system is compromised, individuals may have an impaired ability to clear invading
pathogens. Recent evidence suggests that exposure to PBDEs may compromise the
immune response thereby increasing susceptibility to infectious disease.
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The respiratory tract is continuously exposed to foreign antigens from the
environment. Effective defense mechanisms are therefore essential in the clearance of
potentially infectious antigens. Due to chronic PBDE exposure via inhalation, PBDEs
may compromise the activation of innate immunity, which is essential for lung
homeostasis and the prevention of chronic respiratory conditions.
The macrophage is the sentinel cell of immunity. It acts both directly on foreign
antigens, or pathogens, and indirectly as an antigen-presenting cell. Macrophages reside
in several tissues including the liver, bone, spleen, connective tissue, and lung. In the
absence of a pathogen or in healthy tissue, the macrophage is in a resting state. Upon
activation by a pathogen, the macrophage initiates a series of defense mechanisms such
as phagocytosis and the release of pro-inflammatory cytokines and eicosanoids. Tumor
necrosis factor-a (TNF-a), interleukin-6 (IL-6), and interleukin-ip (IL-1|3) are proinflammatory products phenotypic of classically-activated activated macrophages.
Macrophages have also been shown to produce large quantities of the eicosanoid,
prostaglandin E2 ( P G E 2 ) that has both pro- and anti-inflammatory effects (33). These
chemical signals not only activate physiological processes that support the development
of inflammation, but also communicate with other effector cells such as T-helper
lymphocytes that play a role in the development of acquired immunity.
Alveolar macrophages account for approximately 93% of the macrophages in the
lung (32). Due to their position in the interstitial spaces of the bronchi and alveoli, in the
vascular compartment, and in the alveolus, alveolar macrophages come into contact with
the majority of the inhaled environmental antigens ubiquitous in ambient air (34, 35). It is
therefore thought that activated macrophages that reside in the lung and pleural cavities
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are the main regulators of lung homeostasis (36). Furthermore, through the production of
a multitude of different chemical signals mentioned previously and through the
expression of a number of different receptors, alveolar macrophages have the capability
to communicate with a number of different pathways. For example, alveolar
macrophages express the estrogen receptor and have been shown to be regulated by
estrogen (29).
The immune response to PBDEs is not well characterized. To date, no study has
examined the effects of PBDEs on alveolar macrophage function. Therefore, the
objective of this in vitro study was to determine the impact of PBDEs on the release of
pro-inflammatory products by activated alveolar macrophages and to determine if the
effects on inflammatory products are estrogen-receptor dependent. For the in vitro work
presented in this paper, I used the 3D4/31 commercial porcine alveolar macrophage cell
line.

Materials and Methods

Alveolar macrophages
The 3D4/31 cell line, established from primary porcine alveolar macrophages
(37), was obtained from ATCC; Manassas, VA. Cells were plated out and cryopreserved
in liquid nitrogen at passage #22.

Materials
All materials were purchased from Sigma-Aldrich; St. Louis, MO, unless
indicated otherwise. The DE-71 formulation (a mixture of BDE-99, -47, -100, and -153)
of pentabrominated diphenyl ether (pentaBDE) was purchased from Cambridge Isotope
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Laboratories, Inc.; Andover, MA. The 17|3-estradiol was a gift from Dr. Paul Tsang
(Department of Molecular, Cellular, and Biomedical Sciences; University of New
Hampshire). Enzyme-linked immunosorbant assays (ELISAs) were acquired from R&D
Systems, Inc., Minneapolis, MN to measure the following pro-inflammatory products:
TNF-a, IL-6, IL-lp, and PGE2; and the anti-inflammatory cytokine, IL-10. Cell viability
was confirmed with a lactate dehydrogenase (LDH) assay (Cayman Chemical Company;
Ann Arbor, MI). The RPMI-1640 and non-essential amino acids were purchased from
ATCC; fetal bovine serum (FBS) and porcine serum were purchased from MP
Biomedicals, Solon, OH.

Cell culture protocol
For each experiment, a cryovial of passage #22 3D4/31 porcine alveolar
macrophages were removed from storage, seeded into T75 flask(s) in RPMI growth media
supplemented with 10% FBS and 1% non-essential amino acids, and incubated at
physiological conditions (5% CO2, 37°C). This protocol was adapted, in part, in
collaboration with doctoral student Jay Myers. At 60-70% confluency, cells were
passaged (#23) and seeded into 24-well plate(s) (300,000 cells/well) in RPMI growth
media supplemented with 10% porcine serum and 1% non-essential amino acids and
incubated (5% CO2, 37°C) for 24-hours. After 24-hours, cells were activated by
inoculation with phorbol 12-myristate 13-acetate (PMA). The activating stimulus was
prepared by solubilizing PMA (0.01 mg/mL) and ionomycin (I0) (0.05 mg/mL) in 1%
dimethyl sulfoxide (DMSO). In addition to the activating stimulus, different
concentrations of the experimental treatments and respective vehicle controls were
introduced to the wells and the plate(s) were incubated (5% CO2, 37°C). After a 6-hour
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period, conditioned media was removed, centrifuged, and stored at -80°C until further
analysis.

Experiment 1: PBDE exposure & cytokine and eicosanoid release
The purpose of the first experiment was to determine the effects of PBDEs on
cytokine and eicosanoid release. Stock solutions were prepared by solubilizing the DE-71
mixture in DMSO at seven different concentrations (0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100
ng/mL, 1000 ng/mL, 1500 ng/mL, and 2000 ng/mL). The final DMSO concentration in
the solutions was less than 1%. The following cytokines and PGE2 were measured via
ELISA: TNF-a, IL-6, IL-1(3, and IL-10. For TNF-a measurements, cells were exposed to
PMA and each of the seven different concentrations of DE-71 [n = 18 (0.1 - 2000
ng/mL) and n = 27 (0 ng/mL)]; for all other cytokine and

PGE2

measurements, cells were

exposed to PMA and 0.1, 1, 10, 100, and 1000 ng/mL DE-71 (n = 15-18/treatment).

Experiment 2: Cell Viability
LDH is a cytosolic enzyme released into the culture medium when the cell is
damaged due to either apoptosis or necrosis and can therefore, be used as an indicator of
cytotoxicity. To assess cell viability, cells were seeded in a 96-well plate at a density of
100,000 cells/well in 120 (iL RPMI growth media supplemented with 1% FBS and 1%
non-essential amino acids. After a 24-hour incubation period (5% C0 2 , 37°C),
experimental treatments were added to the wells and the plate was incubated (5% C0 2 ,
37°C) for 6-hours. Experimental treatments included 1) culture medium, 2) DMSO (1%),
3) PMA (0.01 mg/mL) and I0 (0.05 mg/mL) in 1% DMSO, and 4-10) PMA plus seven
different concentrations of DE-71 (0.1, 1, 10, 100, 1000, 1500, 2000 ng/mL). After 6-
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hours, the plate was centrifuged at 400 x g for five minutes. In the corresponding wells of
a new 96-well plate, standards were added in triplicate (n = 3) and 100 [iL of supernatant
from each well of the centrifuged plate was added (n = 8). In accordance with the
manufacturer's protocol, 100 |iL of reaction solution (9.6 mL of assay buffer + 100 [iL of
the following: NAD+, lactic acid, a tetrazolium salt (INT), and reconstituted dipahorase)
was added to each well and the plate was placed on an orbital shaker and incubated at
room temperature with gentle shaking for 30 minutes. The absorbance at 490 nm was
then read with a plate reader. According to the protocol, LDH measures cell death due to
chemical compounds or environmental factors using a coupled two-step reaction. In the
first step, LDH catalyzes the reduction of NAD + to NADH and H + by oxidation of lactate
to pyruvate. Diaphorase then uses NADH and H+ to catalyze the reduction of INT to the
intensely colored formazan, which absorbs at 490-520 nm. The amount of formazan
produced is proportional to the amount of LDH released into the culture medium as a
result of cytotoxicity.

Experiment 3: Estrogen exposure and TNF-a release
The purpose of the third experiment was to determine the effects of estrogen on
TNF-a release. Five different physiological and supraphysiological concentrations of
17P-estradiol were prepared by diluting the 640 |ig/mL stock solution in ethanol (EtOH)
(12.5, 25, 50, 250, and 1000 pg/mL). The final EtOH concentration in the solutions was
less than 1%. Cells were exposed to PMA and each of the five different concentrations of
17p-estradiol (n = 5/treatment). The release of TNF-a was measured via ELISA.
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Experiment 4: Tamoxifen exposure and TNF-a release
Experiment four assessed whether the effects of PBDEs on cytokine release was
mediated via the estrogen receptor. A stock solution was prepared by solubilizing the
tamoxifen in DMSO, so that the final concentration was 10 jiM. Cells were exposed to
PMA and 0.1 and 1 ng/mL of DE-71 and 12.5 pg/mL of 17|3-estradiol with or without the
addition of tamoxifen (n = 9/treatment). The release of TNF-a was measured via ELISA.

Statistical Analysis
Statistical analysis was performed using commercially available statistical
software (SPSS 18; SPSS Inc., Chicago, IL). For all experiments, treatment effects were
determined by analysis of variance (ANOVA) using the general linear model (GLM) with
a Bonferroni adjustment. Differences with ap-value less than 0.05 were considered
statistically significant.

Results
For all experiments, neither cytokines nor eicosanoids were detected in any of the
control conditions when in the absence of PMA (i.e. cells exposed to vehicle alone).
Therefore, only conditions in which measurable levels of product were detected are
reported.

Experiment 1: PBDE exposure & cytokine and eicosanoid release
Alveolar macrophages treated with PMA alone released 340 ± 23 pg/mL of TNFa . Cells exposed to each of the seven different concentrations of DE-71 (0.1, 1, 10, 100,
1000, 1500, and 2000 ng/mL) and PMA (n = 18/treatment) released significantly less
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TNF-a compared to cells exposed to the activating stimulus alone (n = 27) (Figure 7). In
addition, cells exposed to two of the lower concentrations of DE-71 (1 and 10 ng/L) in
addition to PMA, released significantly less TNF-a compared to cells exposed to 1000
ng/mL DE-71 and PMA (Figure 7). Furthermore, the addition of higher concentrations of
DE-71 (1500 and 2000 ng/mL) plus PMA resulted in a significant decrease in TNF-a
compared to cells exposed to 0.1 and 1000 ng/mL DE-71 plus PMA (Figure 7).
A significant suppression in IL-6 was also evident in cells exposed to 0.1, 1, 10,
100, 1000 ng/mL DE-71 compared to PMA alone (n=15/treatment) (Figure 8). All
concentrations of DE-71 (0.1, 1, 10, 100 ng/mL) plus PMA released significantly less IL6 compared to cells exposed to 1000 ng/mL DE-71 plus PMA (Figure 8).
Cells released 1010 ± 101 pg/mL PGE2 when exposed to PMA alone; at 0.1, 1,
10, and 1000 ng/mL DE-71, PGE2 was significantly suppressed (n=18/treatment)
compared to PMA alone (Figure 9).
Cytokines IL-ip and IL-10 were not detected in any treatment or control
conditions (data not shown).
Experiment 2: Cell Viability
Figure 10 shows the LDH cytotoxicity results. Alveolar macrophages in culture
medium released 5.94 ± 0.3 mU/raL LDH. Cells exposed to 1, 100, and 1000 ng/mL DE71 plus PMA released significantly less LDH (3.96 ± 0.1, 3.24 ± 0.2, and 3.38 ± 0.4
mU/mL, respectively) compared to cells in culture medium alone but the same as cells
exposed to PMA alone. When exposed to the highest concentration of DE-71 (2000
ng/mL) plus PMA, cells released significantly more LDH (8.83 ± 0.7 mU/mL) compared
to all other treatments. With the addition of 1500 ng/mL DE-71 plus PMA, cells released

significantly more LDH (5.95 ± 0.6 mU/mL) compared to cells exposed to PMA plus 1,
100, and 1000 ng/mL DE-71, and significantly less LDH compared to cells exposed to
PMA plus 2000 ng/mL DE-71. DE-71 at 2000 ng/mL also was higher than all control
conditions. The experiment was repeated with the same reagents one week later and those
results are reported in the Appendix. No differences in LDH activity were observed
between treatments (see Appendix for interpretation).

Experiment 3: Estrogen exposure and TNF-a release
Alveolar macrophages treated with PMA secreted 204 ± 3.6 pg/mL TNF-a. Cells
exposed to the activating stimulus plus each of the five different concentrations of 17(3estradiol (12.5, 25, 50, 250, and 1000 pg/mL) released significantly less TNF-a
compared to cells exposed to PMA alone (169 ± 3.5, 162 ± 2.5, 159 ± 1.4, 164 ± 3.7, and
169 ± 3.1 pg/mL, respectively) (Figure 11).

Experiment 4: Tamoxifen exposure and TNF-a release
Figure 12 shows the effects of tamoxifen on the release of TNF-a in alveolar
macrophages exposed to varying treatments. Cells treated with tamoxifen in addition to
PMA released significantly less TNF-a compared to PMA alone (102 ± 3.8 vs. 120 ± 2.5
pg/mL, respectively). PMA plus 0.1 and 1 ng/mL DE-71 resulted in a significant
suppression in TNF-a compared to PMA alone (98 ± 3.5 and 97 ± 2.0 pg/mL,
respectively); the suppression remained with the addition of tamoxifen; and there was no
difference compared to PMA plus DE-71 alone. When PMA and 17|3-estradiol were
added to the culture medium, there was a significant reduction in TNF-a compared to
PMA alone (97 ±2.9 pg/mL); a reduction similar to that seen with DE-71 treatment and
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tamoxifen. The reduction in TNF-a was restored when tamoxifen in combination with
PMA and 17|3-estradiol was added to the culture medium (112 ± 3.6 pg/mL).

Discussion
For the first time, we provide evidence that exposure of activated porcine alveolar
macrophages to the PBDE mixture DE-71 suppresses the release of pro-inflammatory
products in vitro and that the suppression at lower concentrations is independent of cell
toxicity. In our model, PBDEs suppress the release of the pro-inflammatory products
TNF-a, IL-6, and PGE2. IL-1|3 and IL-10 were not detected in the culture medium.
Furthermore, we show that there is a similar dampening of TNF-a when activated
porcine alveolar macrophages are in the presence of estrogen; however, the effects seen
with PBDEs are not mediated via the estrogen receptor.
The suppression of TNF-a and IL-6 in the present study may be explained in part
by disrupted signaling of nuclear factor-KB (NF-KB). Due to their position in the alveolar
lumen of the lung, alveolar macrophages are chronically exposed to inhaled
environmental antigens ubiquitous in ambient air (34). Upon encountering an antigen,
macrophages become activated and produce pro-inflammatory cytokines to rid the body
of the pathogen. Pro-inflammatory cytokines TNF-a, IL-6, and IL-1|3 are regulated
through the activation of the transcription factor, NF-KB. In the activated form, N F - K B is
a heterodimer consisting of two proteins, a p65 subunit and a p50 subunit. In
unstimulated cells, NF-KB is located in the cytoplasm bound to an inhibitory protein, IKB that prevents it from entering the nucleus. Upon activation, IK-B kinase (IKK)
phosphorylates IK-B, resulting in degradation of the inhibitory protein and allowing NFKB to translocate to the nucleus to initiate the transcription of various cytokine genes.

Many stimuli have been shown to activate N F - K B including

TNF-a

and protein kinase

C

activators such as PMA, a phorbol ester, and lipopolysaccharide (LPS), a bacterial
endotoxin (28).
TNF-a, IL-6, and IL-ip, all have powerful physiological effects. For example,
TNF-a induces a local inflammatory response (i.e. vasodilation and increased vascular
permeability) that allows fluid, protein, and inflammatory cells to leave the blood stream
and enter the tissue. As a result, the infected tissue becomes inflamed, causing the
characteristic redness, heat, swelling and pain associated with infection.
The eicosanoid PGE2 is a potent inflammatory mediator derived from arachidonic
acid through the cyclooxygenase (COX) enzymes (33). Depending on the inflammatory
stimulus and the receptor to which

PGE2

binds,

PGE2

has the ability to act in either a pro-

or anti-inflammatory manner (38). The pro-inflammatory immune effects of

PGE2

are

similar to those of the pro-inflammatory cytokines (i.e. vasodilation, increased vascular
permeability, fever, and pain), whereas the anti-inflammatory effects include suppressing
lymphocyte proliferation and inhibiting the production of pro-inflammatory cytokines
such as

T N F - a , IL-6,

and

IL-1. PGE2

is not a product of the N F - K B pathway and thus,

the concomitant reduction in P G E 2 seen in the present study suggests that other
mechanisms may be involved.
The failure to detect IL-1 (3 and IL-10 in the culture medium is most likely due to
the inherent heterogeneity of macrophages. Macrophages are a dynamic cell, with the
ability to change their phenotype based on different environmental signals. Based on both
their location (i.e. lung, interstitial, peritoneal, liver, etc.) and their spectrum of activation
(i.e. classically-activated activated, alternatively activated), macrophages have been

25

shown to produce different products (39, 40). In some instances this corresponds to
enhanced cytokine output and phagocytic activity - resulting in a heightened immune
response. This is not, however, always the case. Different environmental signals can give
rise to macrophages that are less equipped to produce cytokines and result in an increased
susceptibility to infection (40). Others in our lab are currently investigating the further
characterization of the 3D4/31 cell line (41).
In the present study, the suppression of TNF-a, IL-6, and PGE2 in cells exposed to
lower concentrations of DE-71 (0.1 - 1500 ng/mL) appears to be independent of
cytotoxicity. Cells exposed to PMA and the highest concentration of DE-71 (2000
ng/mL) released significantly more LDH compared to cells exposed to control conditions
and cells exposed to PMA and lower concentrations of DE-71 (0.1 - 1500 ng/mL). As the
concentration of DE-71 increased, there was a linear decrease in the amount of LDH
released, until 1000 ng/mL DE-71. At that concentration there was an observed linear
increase in LDH that was significant at 2000 ng/mL DE-71. These data suggested that
DE-71 was toxic to alveolar macrophages at a concentration between 1000 and 1500
ng/mL and that the suppression of TNF-a in cells exposed to PMA plus 1500 and 2000
ng/mL DE-71 may be in part, due to cell death. On the other hand, these findings
indicated that at nontoxic levels, there was a linear decrease in LDH that suggested the
effects of PBDEs on production of cytokines and eicosanoids was related to a down
regulation in metabolism of macrophages. For example, PMA has been shown to increase
glucose oxidation in alveolar macrophages (42). Furthermore, Hoppe and Carey (2007)
provide evidence of a significant increase in lipolysis and a significant decrease in
glucose oxidation in adipocytes isolated from Sprague-Dawley rats treated with
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pentaBDEs (43).
The endocrine disrupting potential of PBDEs has largely been studied in regard to
their ability to disrupt thyroid hormone homeostasis. Many environmental pollutants,
however, have proven to be xenoestrogens (44-47). Due to the structural similarity
between PBDEs and other environmental pollutants, such as DDT and PCBs, there there
is high likelihood that PBDEs may be estrogenic as well (48-50). Indeed, Meerts et al.
(2001), provide evidence that several PBDE congeners are agonists of the ERa and ER|3
receptors (49) and in the time since, further evidence of the estrogenic activity of PBDEs
has followed (51, 52). In one study Mercado-Feliciano and Bigsby (2008), showed that
DE-71 behaves as a weak estrogen in both MCF-7 breast cancer cells and ovariectomized
mice (52). In a different study, the same researchers showed that the weak estrogenic
effects of DE-71 are due to the activation of individual congeners, however, the exact
mechanism remains to be elucidated (51).
To determine if PBDEs are acting as xenoestrogens we compared the effects of
PBDEs and estrogen on TNF-a release. Cells exposed to PBDEs showed a dosedependent U-shaped curve. At low concentrations (0.1 and 1 ng/mL DE-71) there was a
steady decline in TNF-a and as the concentration of DE-71 increased (10, 100, 1000
ng/mL DE-71), the production of TNF-a increased - although it remained suppressed
compared to PMA alone throughout.
A similar relationship was described by Tomaszewska et al. (2003), who exposed
mouse leukemic macrophages to estrogen (53). Researchers exposed cells to an activating
stimulus (LPS) alone, and the activating stimulus in addition to five different
concentrations of estrogen (17|3-estradiol) (12.5, 25, 50, 250, 1000 pg/mL). Stimulated
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cells exposed to 12.5, 25, and 50 pg/mL 17|3-estradiol released significantly less TNF-a
compared to stimulated cells alone (p < 0.05); no differences were seen with 250 and
1000 pg/mL 17|3-estradiol. In a recent review the response was described as a dosedependent U-shaped curve, where at physiological concentrations a suppression in TNFa was seen but disappeared at supraphysiological concentrations (29). In the present
study, we exposed porcine alveolar macrophages to an activating stimulus (PMA) alone
and the activating stimulus in addition to the same concentrations of 17|3-estradiol (12.5,
25, 50, 250, 1000 pg/mL) and found a similar relationship. Unlike Tomaszewska et al.
(2003), we found a significant suppression of TNF-a with all concentrations of 17(3estradiol.
Estrogen has an inhibitory effect on TNF-a and other cytokines in many different
cells types (reviewed by (29)). For example, IL-6 is inhibited by estrogen in human
promonocytic cells (54); Vegeto (2001), describes a dose-dependent LPS-induced
suppression of

PGE2

in rat primary microglia cultures exposed to varying levels of 17(5-

estradiol (55); and IL-12 and TNF-a are reduced in mouse dendritic cells with a shift
toward IL-4 and IL-10 (56). Straub (2007), claims that these results are most likely due to
inhibition of N F - K B (29). Ghisletti et al. (2005), provide evidence that the inhibitory
effects of estrogen on N F - K B are mediated by blocking the binding and transcriptional
activity of p65 and preventing nuclear translocation (30). For these experiments, mice
peritoneal macrophages were exposed to LPS alone; 1 and 100 nM of 17|3-estradiol or
tamoxifen (an antagonist of the estrogen receptor) and subsequently LPS; and
competition experiments where tamoxifen was added before the addition of 17|3-estradiol
(100 nM). Immunocytochemical analysis revealed a significant increase in cytoplasmic
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p65 in cells exposed to 17|3-estradiol, indicating the reduced capacity of N F - K B to
translocate to the nucleus and produce pro-inflammatory products. Conversely,
significantly less cytoplasmic p65 was seen in cells exposed to tamoxifen and in the
competition experiments, indicating the translocation of N F - K B to the nucleus and the
production of pro-inflammatory products.
Despite the reported estrogenic activity of PBDEs, it does not appear that they are
acting via the estrogen receptor in the current model. In the present study, tamoxifen, an
antagonist of the estrogen receptors-a and -(3, did not restore the inhibitory effect of
PBDEs in porcine alveolar macrophages; tamoxifen did, however, restore the suppression
seen with 17(3-estradiol. These findings suggest that the PBDEs are acting in an estrogenindependent manner. Mercado-Feliciano and Bigsby (2008), provide evidence that DE-71
can enhance the estrogenic effects beyond those produced by a saturating dose of
estrogen. The researchers suggest that PBDEs are behaving like estrogen through
nonclassical pathways (52).
Endocrine disruptors have the ability to disrupt receptor signaling in a 1) direct
manner by binding to specific hormone receptors or 2) in an indirect manner by binding
to alternative receptors and affecting hormone signaling through various mechanisms
such as competing for common cofactors (5). Once bound to a receptor, endocrine
disruptors act as either: agonists and bind to a specific hormone receptor and mimic that
naturally occurring hormone (e.g. in this case estrogen) and its function, or as an
antagonist and bind to a specific hormone receptor and block the endogenous hormone
from binding (e.g. anti-estrogens such as tamoxifen). When inactive, nuclear receptors
are located in the cytoplasm or in the nucleus bound to chaperone proteins and co-
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repressors. When a ligand binds to the receptor, there is a conformational change
allowing for the dissociation of the chaperone and co-repressor complex and the receptors
to dimerize. If the ligand is an agonist of the receptor, coactivators are recruited. This
facilitates the activated complex to bind to response elements and regulate (activation or
inhibition) transcription of target genes. If the ligand is an antagonist of the receptor,
coactivators are prevented from binding and the complex is not activated.
Given the current findings, it is likely PBDEs are acting indirectly and perhaps
through a different receptor all together, however, no clear evidence exists as to which
receptor is involved. One plausible candidate is the aryl hydrocarbon receptor (AhR).
AhR is a ligand-activated transcription factor that has been shown to be involved with the
cellular responses of many xenobiotics including PCBs (8). The activation of the AhR is
similar to that of other nuclear receptors. AhR resides in the cytoplasm bound to
chaperone proteins. When a ligand binds, AhR is translocated to the nucleus, the
chaperone proteins are dissociated, and AhR dimerizes with the AhR nuclear translocator
(ARNT). The ligand-AhR-ARNT complex can then bind to response elements, which
leads to gene transcription (57). The ligand-AhR-ARNT has also been reported to
downregulate the transcription of some genes (58). In the same study, Tijet et al. (2006),
goes on to say that estrogen and AhR are reciprocally regulated because of the overlap
and antagonism of the two pathways. Nonetheless, a recent review examining the effects
of PBDEs on different receptors, Luthe et al. (2008), speculate that due to their structural
conformation, PBDEs do not possess AhR activity (59). Further research is needed to
address these issues.
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Another possibility is a recently discovered orphan nuclear receptor. In 1998,
three independent research groups discovered and named the receptor the steroid and
xenobiotic receptor (SXR) (the name I will use throughout), the pregnane X receptor
(PXR), and the pregnane activated receptor (PAR), respectively (60-62). SXR is a
nuclear receptor that has been described as a xenobiotic sensor that regulates the
clearance of xenobiotics in the liver and intestine (63). Interestingly, it has also been
shown to be highly expressed in alveolar macrophages (64). Many endogenous
compounds (e.g. steroids such as estrogen) and exogenous compounds (e.g.
pharmaceuticals such as tamoxifen and endocrine disruptors such as PBDEs) are known
activators of SXR (63). Due to this capability, cross-talk between SXR and other nuclear
receptors exists. For example, SXR has been shown to interact with NF-KB, thereby
providing a potential link between SXR ligands and inflammation (63). Many studies
have shown that activation of SXR suppresses the effects of NF-KB, although the exact
mechanism remains to be elucidated. Our data from the tamoxifen experiments suggest
the suppressive effects of PBDEs may be acting via SXR. Furthermore, tamoxifen has
been shown to be a potent activator of the SXR and may therefore explain the apparent
decrease in TNF-a with tamoxifen alone, as well as the redundant effects seen with
PBDEs and tamoxifen (65). Conversely, in the tamoxifen study mentioned earlier,
Ghisletti et al. (2005) saw a negligible amount of cytoplasmic p65 with LPS and
tamoxifen - an indication of increased pro-inflammatory cytokines. These apparently
disparate results could be explained by the inherent cell- or species-specific differences
(i.e. mouse peritoneal vs. porcine alveolar macrophages). Another possible explanation
could be the dose of tamoxifen (1 and 100 nM vs. 10 |aM).

31

In summary, proper functioning of the macrophage through chemical signals such
as cytokines and eicoanoids is essential for the innate immune response and host defense.
Thus, the observed suppression in pro-inflammatory cytokine and eicosanoid production
in PMA-activated porcine alveolar macrophages exposed to DE-71 is a novel finding.
Furthermore, we show that the suppression seen with DE-71 is similar to that of estrogen;
however, our results demonstrate that the inhibitory effects of DE-71 are not mediated via
the estrogen receptor. Given the present findings, there is concern that PBDEs may
compromise innate immune function, thereby increasing the susceptibility and the time
required to resolve an infection. These data suggest that subacute chronic inflammation
may be explained in part by persistent exposure to airborne PBDEs. Whether these
effects are seen in vivo, remains to be determined.
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CHAPTER III

IMPLICATIONS

The concept of flame retardants is a good one. Reducing the flammability and
decreasing the burn rate of products so that there is an increased time to escape in the
event of a fire is critical. There is a growing body of evidence that chronic exposure to
flame retardants may have important (yet not well understood) health risks. Research
conducted in our laboratory suggests that exposure to lower concentrations of PBDEs
may increase an individual's susceptibility to and the time needed to resolve an infection.
These findings could have important public health implications.
Respiratory infections (e.g. rhinovirus and influenza) are the most prevalent and
pathogenic form of infectious disease (31, 32). Infection occurs when the host encounters
a pathogen, which invades and infects the host's respiratory mucosal tissues. Once the
pathogen invades the cells, the innate immune response is initiated (see Chapter I:
Immune Response for a detailed explanation). The process of resolving an infection takes
approximately 7-14 days and is characterized by coughing, sore throat, fever, nasal/ear
congestion, fatigue, and body aches (31). We provide evidence that exposure to PBDEs
may compromise this response.
Porcine alveolar macrophage exposed to PBDEs, show a marked reduction in the
pro-inflammatory response, leading to a decrease in effector cell (i.e. macrophage)
function and an inappropriate development of the adaptive immune response. The
suppression of the immune system seen with exposure to PBDEs, especially at lower
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concentrations, may provide an 'open window' of susceptibility to infection. During this
'open window' of susceptibility, viruses and bacteria may gain entry, thereby increasing
the risk and/or duration of infection.
Furthermore, the suppression in pro-inflammatory cytokines of the innate immune
response may compromise the role of the alveolar macrophage in eliciting adaptive
immunity. It is therefore plausible that exposure to PBDEs could play a role in the
development of atopic disease and chronic inflammatory disorders. The decreased ability
of alveolar macrophages to generate pro-inflammatory cytokines could shift acquired
immunity away from cell mediated and more toward humoral immunity. A shift toward
the anti-inflammatory Th2 phenotype and away from the pro-inflammatory ThI
phenotype has been shown in a number of diseased and inflammatory conditions. For
example, a shift toward a Th2 response is seen in allergic diseases such as asthma,
allergic rhinitis, food hypersensitivity, atopic dermatitis; and chronic respiratory disorders
(31, 66). The same trend may occur with chronic exposure to PBDEs - that is, the ThI
response may be suppressed too much - allowing pathogens to gain entry and leading to
an increased susceptibility to infection.
Current data suggests there is a relationship between exposure to PBDEs and the
susceptibility to infection. In light of these suspected health conditions, research and
legislation should be directed toward further investigation of how PBDEs may be
affecting human and animal health, and at the same time, developing alternative flame
retardant products. Due to the persistence of PBDEs in the environment, proper disposal
of products containing PBDEs is essential. Furthermore, it is important that individuals
recognize the risks associated with chemical pollutants and employ ways to reduce
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exposure. Most importantly, populations that are most susceptible to infection - pregnant
women, infants, and children - may be more at risk.
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TABLES

Table 1.
Group

Examples

Herbicides

Alachlor, Atrazine, Nitrofen, Trifluralin

Fungicides

Hexachlorobenzene, Maneb, Zineb

Insecticides

Carbaryl, DDT, Dieldrin, Organophosphates, Toxaphene

Industrial chemicals

Bisphenol A, Dioxins, PBDEs, PCBs, Phthalates, Styrenes

Heavy metals

Cadmium, Lead, Mercury

Main groups and examples of endocrine-disrupting chemicals [adapted from (3, 67)].
DDT, dichlorodiphenyltrichloroethane; PBDEs, polybrominated diphenyl ethers; PCBs,
polychlorinated biphenyls.
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Table 2.
Major PBDE congeners or mixtures
BDE-47

2,2', 4,4'-tetrabromodiphenyl ether

BDE-99

2,2', 4,4',5-pentabromodiphenyl ether

BDE-100

2,2', 4,4',6-pentabromodiphenyl ether

BDE-153

2,2', 4,4',5,5'-hexabromodiphenyl ether

BDE-154

2,2', 4,4',5,6'-hexabromodiphenyl ether

BDE-209

Decabromodiphenyl ether

DE-71

PentaBDE technical mixture (BDE-99, 44%;
BDE-47, 32%; BDE-100, 9%; BDE-153, 4%)

DE-79

Adapted from (16).

OctaBDE technical mixture (BDE-183, 35%;
BDE-197, 22%; BDE-207, 14%; BDE-196, 9%)

Table 2.
Serum levels of PBDE's in a family from Northern California in 2004
Age

X(5)PBDEsa

Father

35

64

Mother

36

106

Female child

5

247

Male toddler

1.5

418

Family member

PBDE levels are expressed as ng/g lipid weight.
a
Sum of five BDE's (BDE-47, -99, -100, -153, -154).
Adapted from (16).

FIGURES

Figure 1. The glands of the endocrine system [Illustration by K. Born (1995) (68)].
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Figure 2. The body's integrating systems and the cross-talk that occurs between the
different systems via hormones and other chemical messengers (adapted from figure
created by William Condon, Ph.D.).
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Figure 3. Systems and organs targeted by endocrine disrupting chemicals (4).

J

h
\
v. MM

St-

•tswn5

V

Figure 4. Structure of: A. polybrominated diphenyl ethers (PBDEs), B. polychlorinated
biphenyls (PCBs), and C. dichlorodiphenyltrichloroethane (DDT).
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Figure 5. The intricate network of the immune system (adapted from figure created by
Amy Moore, Ph.D.).
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Figure 6. Overview of the immune defense mechanisms against respiratory pathogens
[adapted from (31)].
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Figure 7. Effects of PBDEs on TNF-a release by activated porcine alveolar
macrophages. All treatments included PMA (10 [iL/mL). Values are means ± SE; n =
(0.1-2000 ng/mL) and n = 27 (0 ng/mL). Means with different letters are significantly
different (p < 0.05).
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Figure 8. Effects of PBDEs on IL-6 release by activated porcine alveolar macrophages.
All treatments included PMA (10 jxL/mL). Values are means ± SE; n = 15/treatment.
Means with different letters are significantly different (p < 0.05).
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Figure 9. Effects of PBDEs on P G E 2 release by activated porcine alveolar macrophages.
All treatments included PMA (10 fxL/mL). Values are means ± SE; n = 18/treatment.
Means with different letters are significantly different {p < 0.05).
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Figure 10. Lactate dehydrogenase (LDH) cytotoxicity. Cells were exposed to culture
medium (CM); 1% dimethyl sulfoxide (DMSO); phorbol 12-myristate 13-acetate (PMA)
(0.01 mg/mL) and ionomycin (Io) (0.05 mg/mL) in 1% DMSO; and PMA plus seven
different concentrations of DE-71. Values are means ± SE; n=8/treatment. Means with
different letters are significantly different (p < 0.05).
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Figure 11. Effects of 17|3-estradiol (17|3-E2) on TNF-a release by activated porcine
alveolar macrophages. All treatments included PMA (10 (aL/mL). Values are means ±
SE; n = 5/treatment. Means with different letters are significantly different (p < 0.05).
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Figure 12. Effects of tamoxifen (TAM) on TNF-a release by activated porcine alveolar
macrophages. All treatments included PMA (10 [xL/mL). Values are means ± SE; n =
9/treatment. Means with different letters are significantly different (p < 0.05).
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APPENDIX

Lactate Dehydrogenase (LDH) Cytotoxicity
LDH activity (mU/mL)
Controls

DE-71

Culture medium

0.659 ±0.133

DMSO

0.511 ±0.133

PMA

0.366 ±0.133

0.1 ng/mL

0.554 ±0.133

1 ng/mL

0.490 ±0.133

10 ng/mL

0.260 ±0.133

100 ng/mL

0.197 ±0.133

1000 ng/mL

0.261 ±0.133

1500 ng/mL

0.156± 0.133

2000 ng/mL

0.156 ± 0.133

Cells were exposed to culture medium; dimethyl sulfoxide (DMSO)(l%); phorbol 12myristate 13-acetate (PMA) (0.01 mg/mL) and ionomycin (Io) (0.05 mg/mL) in 1%
DMSO; and PMA plus seven different concentrations of DE-71. Values are means ± SE;
n=8/treatment.

To confirm the results obtained in the first experiment, a second LDH cytotoxicity
assay was performed one week later. In the second experiment, no difference in LDH
activity was observed between treatments. Despite the conflicting results at the higher
concentrations (1500 and 2000 ng/mL) and the magnitude of difference in the levels of
LDH in the two LDH cytotoxicity experiments, the trend for the lower concentrations
(0.1 - 1000 ng/mL DE-71) remains the same (i.e. a linear decrease in LDH). The
disparity of the magnitude of difference in the levels of LDH in the two experiments is
most likely due to the time of the assay. In the first LDH experiment, all reagents were
prepared, the assay was performed, and the leftover reagents were stored for later use. In
the second LDH experiment, the leftover reagents were used - which could explain the
decreased sensitivity of the assay.
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